Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced that Chief Executive Officer Abraham Ceesay will present at the 42^nd Annual J. P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 8:00 a.m. Pacific Time.

About Rapport (www.rapportrx.com)

Rapport is developing a new class of precision neuromedicines that could give patients better alternatives to current treatments for neurological and psychiatric diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance and discontinuation. By more precisely targeting the neural circuits and cell types where diseases originate, Rapport’s approach has the potential to reduce the unwanted drug-target interactions that lead to these issues. The company’s platform, built and refined over the past decade by its founding scientific team, achieves precision through the discovery and targeting of receptor-associated proteins, or RAPs, which display regional or neural circuit-specific expression. Rapport has ongoing clinical trials and discovery-stage programs in epilepsy, hearing, pain, and psychiatric disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103096441/en/